Red Book Online Quick Search Advanced Search

This Article Images Only Full Version Services E-mail this link to a friend Related text in Red Book Add to My File Cabinet Download to citation manager Articles in Pediatrics Section 1 Section 2 Section 3 Section 4 Section 5 Appendices

The first 300 words of the full text of this section appear below.

Section 3. Summaries of Infectious Diseases

Mumps

Clinical Manifestations
Etiology
Epidemiology
Diagnostic Tests
Treatment
Isolation of the Hospitalized Patient
Control Measures

Top Next

CLINICAL MANIFESTATIONS: Mumps is a systemic disease characterized by swelling of one or more of the salivary glands, usually the parotid glands. Approximately one third of infections do not cause clinically apparent salivary gland swelling and may manifest primarily as respiratory tract infection. More than 50% of people with mumps have cerebrospinal fluid pleocytosis, but fewer than 10% have symptoms of central nervous system infection. Orchitis is a common complication after puberty, but sterility rarely occurs. Other rare complications include arthritis, thyroiditis, mastitis, glomerulonephritis, myocarditis, endocardial fibroelastosis, thrombocytopenia, cerebellar ataxia, transverse myelitis, ascending polyradiculitis, pancreatitis, oophoritis, and hearing impairment. In the absence of immunization, mumps typically occurs during childhood. Infection occurring among adults is more likely to be severe, and death resulting from mumps and its complications, although rare, occurs most often in adults. Mumps during the first trimester of pregnancy is associated with an increased rate of spontaneous abortion. Although mumps can cross the placenta, no evidence exists that this results in congenital malformation.

Top Previous Next

ETIOLOGY: Mumps is caused by an RNA virus classified as a Rubulavirus in the Paramyxoviridae family. Other causes of parotitis include infection with cytomegalovirus, parainfluenza virus types 1 and 3, influenza A virus, coxsackieviruses and other enteroviruses, lymphocytic choriomeningitis virus, human immunodeficiency virus (HIV), Staphylococcus aureus, nontuberculous mycobacterium, and less often, other gram-positive and gram-negative bacteria; salivary duct calculi; starch ingestion; drug reactions (eg, phenylbutazone, thiouracil, iodides); and metabolic disorders (diabetes mellitus, cirrhosis, and malnutrition).

Top Previous Next

EPIDEMIOLOGY: Mumps occurs worldwide, and humans are the only known natural hosts. The virus is spread by contact with infected respiratory tract secretions. Historically, the peak incidence was between January and May; however, seasonality no longer is evident . . . [Go to Full Text]

Related text in Red Book:

Vaccine Safety and Contraindications

Red Book 2006: 39-41. [Extract] [Full Version]  

Simultaneous Administration of Multiple Vaccines

Red Book 2006: 34. [Extract] [Full Version]  

Immunocompromised Children

Red Book 2006: 71-85. [Extract] [Full Version]  

Rubella

Red Book 2006: 574-579. [Extract] [Full Version]  

Varicella-Zoster Infections

Red Book 2006: 711-725. [Extract] [Full Version]  

Human Immunodeficiency Virus Infection

Red Book 2006: 378-401. [Extract] [Full Version]  

Measles

Red Book 2006: 441-452. [Extract] [Full Version]  

Mycoplasma pneumoniae Infections

Red Book 2006: 468-470. [Extract] [Full Version]  

This topic has been referenced by these articles:

• Klein, J. O., Myers, M. G. (2006). Vaccine shortages: why they occur and what needs to be done to strengthen vaccine supply.. Pediatrics 117: 2269-2275 [Full Version]  
• Perez, E. E., Bokszczanin, A., McDonald-McGinn, D., Zackai, E. H., Sullivan, K. E. (2003). Safety of Live Viral Vaccines in Patients With Chromosome 22q11.2 Deletion Syndrome (DiGeorge Syndrome/Velocardiofacial Syndrome). Pediatrics 112: e325-325 [Abstract] [Full Version]  
• Bonilla, F. A. (2004). SAFETY OF LIVE VIRAL VACCINES IN PATIENTS WITH CHROMOSOME 22Q11.2 DELETION SYNDROME (DiGEORGE SYNDROME/VELOCARDIOFACIAL SYNDROME). Pediatrics 114: 550-550 [Full Version]  
• (2006). Reisinger KS, Hoffman Brown ML, Xu J, et al. A Combination Measles, Mumps, Rubella, and Varicella Vaccine (ProQuad) Given to 4- to 6-Year-Old Healthy Children Vaccinated Previously With M-M-RII and Varivax. PEDIATRICS 2006;117:265-272.. Pediatrics 117: 2338-2338 [Full Version]  
• Pool, V., Braun, M. M., Kelso, J. M., Mootrey, G., Chen, R. T., Yunginger, J. W., Jacobson, R. M., Gargiullo, P. M. (2002). Prevalence of Anti-Gelatin IgE Antibodies in People With Anaphylaxis After Measles-Mumps-Rubella Vaccine in the United States. Pediatrics 110: e71-71 [Abstract] [Full Version]  
• Bekker, V., Scherpbier, H., Pajkrt, D., Jurriaans, S., Zaaijer, H., Kuijpers, T. W. (2006). Persistent Humoral Immune Defect in Highly Active Antiretroviral Therapy-Treated Children With HIV-1 Infection: Loss of Specific Antibodies Against Attenuated Vaccine Strains and Natural Viral Infection. Pediatrics 118: e315-e322 [Abstract] [Full Version]  
• Maloney, J., Sicherer, S. H. (2005). No Epidemiological Evidence for Infant Vaccination to Cause Allergic Disease. Pediatrics 116: 542-542 [Full Version]  
• Leitch, R., Halsey, N., Hyman, S. L. (2002). MMR--Separate Administration--Has It Been Done?. Pediatrics 109: 172-172 [Full Version]  
• Piedra, P. A., Gaglani, M. J., Riggs, M., Herschler, G., Fewlass, C., Watts, M., Kozinetz, C., Hessel, C., Glezen, W. P. (2005). Live Attenuated Influenza Vaccine, Trivalent, Is Safe in Healthy Children 18 Months to 4 Years, 5 to 9 Years, and 10 to 18 Years of Age in a Community-Based, Nonrandomized, Open-Label Trial. Pediatrics 116: e397-e407 [Abstract] [Full Version]  
• Miller, L. C., Comfort, K., Kelly, N. (2001). Immunization Status of Internationally Adopted Children. Pediatrics 108: 1050-1051 [Full Version]  
• Rosenthal, J., Rodewald, L., McCauley, M., Berman, S., Irigoyen, M., Sawyer, M., Yusuf, H., Davis, R., Kalton, G. (2004). Immunization Coverage Levels Among 19- to 35-Month-Old Children in 4 Diverse, Medically Underserved Areas of the United States. Pediatrics 113: e296-e302 [Abstract] [Full Version]  
• Posfay-Barbe, K. M., Heininger, U., Aebi, C., Desgrandchamps, D., Vaudaux, B., Siegrist, C.-A. (2005). How Do Physicians Immunize Their Own Children? Differences Among Pediatricians and Nonpediatricians. Pediatrics 116: e623-e633 [Abstract] [Full Version]  
• Virtanen, M., Peltola, H., Paunio, M., Heinonen, O. P. (2000). Day-to-Day Reactogenicity and the Healthy Vaccinee Effect of Measles-Mumps-Rubella Vaccination. Pediatrics 106: 62e-62 [Abstract] [Full Version]  
• Nilsson, A., De Milito, A., Engstrom, P., Nordin, M., Narita, M., Grillner, L., Chiodi, F., Bjork, O. (2002). Current Chemotherapy Protocols for Childhood Acute Lymphoblastic Leukemia Induce Loss of Humoral Immunity to Viral Vaccination Antigens. Pediatrics 109: e91-91 [Abstract] [Full Version]  
• Patja, A., Mäkinen-Kiljunen, S., Davidkin, I., Paunio, M., Peltola, H. (2001). Allergic Reactions to Measles-Mumps-Rubella Vaccination. Pediatrics 107: 27e-27 [Abstract] [Full Version]  
• Reisinger, K. S., Hoffman Brown, M. L., Xu, J., Sullivan, B. J., Marshall, G. S., Nauert, B., Matson, D. O., Silas, P. E., Protocol 014 Study Group for ProQuad, , Schodel, F., Gress, J. O., Kuter, B. J. (2006). A Combination Measles, Mumps, Rubella, and Varicella Vaccine (ProQuad) Given to 4- to 6-Year-Old Healthy Children Vaccinated Previously With M-M-RII and Varivax. Pediatrics 117: 265-272 [Abstract] [Full Version]  

Site Requirements | Privacy Policy | Core Values, Vision, and Mission Statement
The recommendations in this online publication do not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.
Copyright © 2006 American Academy of Pediatrics